Esplora le valutazioni degli analisti di Immutep e gli obiettivi di prezzo (NASDAQ:IMMP) su Benzinga. Rimani aggiornato sulle opinioni degli esperti e sulle previsioni per le azioni IMMP.

Valutazioni degli analisti, obiettivi di prezzo, previsioni

Immutep

Immutep Limited - American Depositary Shares

Immutep Ltd

Abeona Therapeutics

Achieve Life Sciences, Inc. - Common Shares

Achieve Life Sciences

Allogene Therapeutics, Inc. - Common Stock

Allogene Therapeutics

Armata Pharmaceuticals, Inc. Common Stock

Armata Pharmaceuticals

Avalo Therapeutics

Black Diamond Therapeutics, Inc. - Common Stock

Black Diamond Therapeutic

Cabaletta Bio

Candel Therapeutics

Capricor Therapeutics, Inc. - Common Stock

Capricor Therapeutics

C4 Therapeutics

Editas Medicine

ETHZilla

Foghorn Therapeutics

Humacyte

Insight Molecular Diagnostics Inc. - Common Stock

Insight Molecular

Larimar Therapeutics, Inc. - Common Stock

Larimar Therapeutics

Mereo BioPharma Group plc - American Depositary Shares

Mereo BioPharma Group

Palisade Bio

Puma Biotechnology

ProQR Therapeutics N.V. - Ordinary Shares

ProQR Therapeutics

Pyxis Oncology

Sagimet Biosciences Inc. - Series A Common Stock

Sagimet Biosciences

Tenaya Therapeutics

Vanda Pharmaceuticals Inc. - Common Stock

Vanda Pharmaceuticals

Voyager Therapeutics, Inc. - Common Stock

Voyager Therapeutics

Immutep (IMMP) Previsione

Notizie

Utili

Quote.Nav.option-chain

Valutazioni degli analisti

Vendite allo scoperto

Rapporto azionario

Immutep Ltd is a Phase three clinical biotechnology company developing novel Lymphocyte Activation Gene-3 (LAG-3) related immunotherapies for cancer and autoimmune disease. It has a diversified product portfolio that harnesses LAG-3's ability to stimulate the body's immune response to fight cancer or suppress the immune system to treat autoimmune disease. The company is focused on advancing its product candidate, eftilagimod alfa (efti), through its registrational Phase three clinical trial towards marketing approval in first-line non-small cell lung cancer (1L NSCLC). The other product candidates in its portfolio include TACTI-004, TACTI-003, AIPAC-003, TACTI-002, INSIGHT-005, and others, being developed as potential therapies for various cancers and autoimmune diseases.

Comments

Immutep Valutazioni degli analisti

Valutazioni degli analisti

Valutazioni degli analisti, obiettivi di prezzo, previsioni

Valutazioni degli analisti per Immutep

FAQ

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO